US · XNCR
Xencor, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Pasadena, CA 91016
- Website
- xencor.com
Price · as of 2025-12-31
$12.69
Market cap 911.91M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $24.61 | +93.93% |
| Intrinsic Value(DCF) | $6.32 | -50.2% |
| Graham-Dodd Method(GD) | $2.37 | -81.32% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $12.50 | $39.76 | $1.98 | $0.00 | $0.00 |
| 2014 | $14.54 | $38.08 | $1.37 | $0.00 | $0.00 |
| 2015 | $12.50 | $100.72 | $17,266.05 | $1.91 | $0.00 |
| 2016 | $24.82 | $75.72 | $435,603.98 | $10.47 | $122.50 |
| 2017 | $32.72 | $60.04 | $51.39 | $0.80 | $50.68 |
| 2018 | $29.14 | $28.79 | $8.53 | $3.16 | $0.00 |
| 2019 | $31.54 | $106.27 | $1,933.76 | $12.87 | $133.92 |
| 2020 | $47.03 | $56.92 | $21.74 | $3.95 | $15.42 |
| 2021 | $27.49 | $68.30 | $9,616.37 | $19.64 | $179.66 |
| 2022 | $26.99 | $73.71 | $5.45 | $7.57 | $28.05 |
| 2023 | $24.25 | $97.74 | $6.90 | $0.05 | $0.00 |
| 2024 | $13.87 | $18.88 | $4.07 | $0.00 | $96.81 |
| 2025 | $12.30 | $24.61 | $1.70 | $2.37 | $0.00 |
AI valuation
Our deep-learning model estimates Xencor, Inc.'s (XNCR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $24.61
- Current price
- $12.69
- AI upside
- +93.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.32
-50.2% upside
Graham-Dodd
$2.37
-81.32% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XNCR | Xencor, Inc. | $12.69 | 911.91M | +94% | -50% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
| ANAB | AnaptysBio, Inc. | $55.05 | 1.52B | -23% | +23,485% | — | — | -3.19 | 6.54 | 5.08 | -4.83 | — | 6.54 | -79.49% | -125.93% | -159.10% | -182.71% | 99.94% | -31.02% | 5.21 | -2.29 | 9.51 | 9.38 | -2.66 | -1579.00% | 43203.00% | 1158.00% | -29.26% | -2.98 | 117.98% | 0.00% | 0.00% | 0.10% | -3.90 | -3.30 | 4.91 | -1.16 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| MNMD | Mind Medicine (MindMed) I… | $17.47 | 1.32B | — | — | — | — | -4.43 | 1.99 | — | -2.21 | — | 2.17 | — | — | — | -68.01% | 1162.37% | -50.94% | 0.09 | -45.52 | 7.25 | 7.05 | 2.42 | -9385.00% | — | 2294.00% | -16.44% | -2.04 | 885.11% | 0.00% | 0.00% | 34.56% | -2.21 | -2.90 | — | 2.74 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| NRIX | Nurix Therapeutics, Inc. | $15.97 | 1.38B | +65% | -49% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| OCS | Oculis Holding AG | $29.41 | 1.68B | — | — | — | — | -7.08 | 8.29 | 886.66 | -7.02 | — | 10.12 | -7492.27% | -10671.14% | -12503.94% | -102.85% | 682.30% | -73.23% | 0.02 | — | 2.37 | 2.25 | 0.36 | -2862.00% | — | -1144.00% | -7.85% | -1.07 | 445.69% | 0.00% | 0.00% | 0.00% | -6.98 | -10.70 | 744.55 | 3.05 |
| PHAT | Phathom Pharmaceuticals, … | $12.56 | 979.85M | +275% | +76,266% | — | — | -3.78 | -1.91 | 4.77 | -4.45 | — | -1.91 | 87.09% | -91.36% | -126.35% | 63.97% | 57.00% | -69.41% | -0.01 | -2.35 | 1.73 | 1.58 | 0.80 | -4272.00% | 21693.00% | -3743.00% | -19.98% | -1.26 | 59.50% | 0.00% | 0.00% | 46.07% | -4.43 | -4.24 | 4.05 | -8.21 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
| URGN | UroGen Pharma Ltd. | $21.70 | 1.02B | -0% | -82% | — | — | -3.32 | -47.83 | 4.66 | -3.23 | — | -47.83 | 90.18% | -107.06% | -140.35% | 342.83% | 86.07% | -54.68% | -14.02 | -7.73 | 6.01 | 5.59 | 0.51 | -1662.00% | 929.00% | 2676.00% | -23.05% | -2.11 | 86.32% | 0.00% | 0.00% | 12.59% | -3.18 | -3.17 | 3.40 | -2.93 |
About Xencor, Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
- CEO
- Bassil I. Dahiyat
- Employees
- 250
- Beta
- 0.98
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.32 ÷ $12.69) − 1 = -50.2% (DCF, example).